The debate over drug-price negotiation policies, particularly those in the Inflation Reduction Act, has become the centerpiece of discussions about healthcare affordability, job creation and medical innovation. Finding a balance between making lifesaving medications affordable while sustaining the incentives for medical innovation is critical. There is no denying the need to alleviate the burden of healthcare costs today, but policy must consider the entire drug supply chain, and take steps to avoid…
Source link
- Blogger Comment
- Facebook Comment
Subscribe to:
Post Comments
(
Atom
)
0 comments:
Post a Comment